Lambert Assoumou
A5091495073- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- COVID-19 Clinical Research Studies
- Lipoproteins and Cardiovascular Health
- Long-Term Effects of COVID-19
- HIV, Drug Use, Sexual Risk
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- Pharmaceutical Economics and Policy
- Viral-associated cancers and disorders
- Liver Disease Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Herpesvirus Infections and Treatments
- Reproductive tract infections research
- Biosimilars and Bioanalytical Methods
- Chemokine receptors and signaling
- Mosquito-borne diseases and control
- Polyomavirus and related diseases
- Biochemical and Molecular Research
- vaccines and immunoinformatics approaches
Institut Pierre Louis d‘Épidémiologie et de Santé Publique
2016-2025
Sorbonne Université
2016-2025
Inserm
2016-2025
Assistance Publique – Hôpitaux de Paris
2015-2024
Université Paris Cité
2008-2023
Université Sorbonne Paris Nord
2023
Sorbonne University Abu Dhabi
2022
Hôpital Jean-Verdier
2020
Sorbonne Paris Cité
2015-2019
Santé Publique France
2019
Objective: To evaluate the change in bone mineral density (BMD) at specific sites patients initiating antiretroviral therapy a substudy of ANRS 121 trial. Methods: Antiretroviral-naive were randomized (2: 1: 1) into three treatment strategy arms: nonnucleoside reverse transcriptase inhibitor (NNRTI) and boosted protease (PI/r), PI/r two nucleoside inhibitors (NRTIs) or an NNRTI NRTIs. Hip lumbar spine standardized BMD evaluated baseline week 48 by dual X-ray absorptiometry central reading...
A double-blinded, controlled study of vaccination untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection 3 doses autologous monocyte-derived dendritic cells (MD-DCs) pulsed heat inactivated HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first (primary end point), a modest significant decrease in plasma viral load observed vaccine recipients, compared control subjects (P = .03). In addition, the change...
Abstract Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients COVID-19 were randomised 4 mg once daily or placebo, added standard of care. The primary...
Background Some migrant men who have sex with (MSM) acquire HIV in France. Aims We investigated, MSM receiving care France, the (i) rate of post-migration-HIV acquisition (ii) delay between arrival and (iii) factors affecting within 1 year after migration. Methods This cross-sectional study focused on ≥ 18-year-old born outside Paris region. Information migration history, socioeconomic condition, sexual activity, health was collected May 2021–June 2022 through self-administered...
To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to dolutegravir (DTG) regimen.
The main aim of this study was to determine whether HIV replication can be controlled following interruption treatment started early in the course infection (CD4 >350 cells/μl and viral load <50 000 copies/ml), but not during primary infection.Patients enrolled a multicenter trial (ANRS 116 SALTO) with CD4 above 450 below 400 copies/ml at were selected for second analysis. We determined proportion patients whose plasma HIV-RNA remained first 12 months interruption, baseline factors...
Objectives: To investigate the potential for combination antiretroviral therapy (cART)-free remission following analytic treatment interruption (ATI) in chronically HIV-infected patients with ultralow cell-associated DNA. Methods: Pilot study of (pts) plasma viral load (pVL) less than 50 copies/ml more 2 years on cART, CD4+ above 500 cells/μl, CD4+/CD8+ 0.9, nadir 300 cells/μl and HIV-DNA below 100 copies/106 peripheral blood mononuclear cells (PBMCs), undergoing interruption. Ultrasensitive...
Background: HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver disease. Noninvasive tests steatosis, steatohepatitis (NASH), and fibrosis have been poorly assessed in this population. Using biopsy (LB) as a reference, we the accuracy noninvasive methods for their respective diagnosis: magnetic resonance imaging proton-density-fat-fraction (MRI-PDFF), FibroScan/controlled attenuation parameter (CAP), biochemical tests. Methods: We enrolled antiretroviral...
HIV infection and its treatment with protease inhibitors, especially when boosted ritonavir, can cause lipid disorders. Statins, the exception of fluvastatin, pravastatin rosuvastatin, interact inhibitor metabolism via CYP450. Pravastatin is recommended for patients inhibitor-associated dyslipidemia. Rosuvastatin statin most effective on low-density lipoprotein cholesterol (LDL-c) in non-HIV patients.HIV-1-infected treated were randomized to receive either rosuvastatin 10 mg/day or 40...
Objective: Evaluate immunogenicity and clinical efficacy of two immunization strategies with the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients. Design: Randomized, double-blind, placebo-controlled, phase II study vCP1452 chronically patients on therapy CD4 T-cell count more than 350 cells/μl, nadir less 400 cells/μl pHIV-RNA copies/ml. Patients were equally randomized to four injections at weeks 0, 4, 8, 20; three placebo. The primary endpoint was week 24...
As a first step towards HIV cure, we assessed strategy of antiretroviral therapy (ART) intensification followed by interleukin-7 (IL-7) used as an HIV-reactivating agent. A multicentre, randomized clinical trial included patients on suppressive ART with CD4 cell counts at least 350/μl and HIV-DNA between 10 1000 copies/10 peripheral blood mononuclear cells (PBMCs). After 8-week raltegravir maraviroc intensification, were to alone or 3 weekly IL-7 injections weeks 8, 9 10. The primary...
Abstract Objectives The objectives of this study were to determine the prevalence and patterns resistance integrase strand transfer inhibitors (INSTIs) in patients experiencing virological failure on raltegravir-based ART impact susceptibility INSTIs (raltegravir, elvitegravir dolutegravir). Patients methods Data collected from 502 treatment-experienced failing a raltegravir-containing regimen multicentre study. Reverse transcriptase, protease sequenced at for each patient. INSTI...
Silent cerebral small-vessel disease (CSVD) is defined as white matter hyperintensities, silent brain infarction, or microbleeds. CSVD responsible for future vascular events, cognitive impairment, frailty, and shorter survival. prevalence among middle-aged people living with well-controlled human immunodeficiency virus (HIV) infection (PLHIV) unknown.The French National Agency Research on AIDS Viral Hepatitis (ANRS) EP51 Microvascular Brain Retina Kidney Study (MicroBREAK; NCT02082574) a...
Abstract Background Integrase inhibitors have been recently linked to a higher risk for hypertension. In NEAT022 randomized trial, virologically suppressed persons with human immunodeficiency virus (HIV, PWH) high cardiovascular switched from protease dolutegravir either immediately (DTG-I) or after 48 weeks (DTG-D). Methods Primary endpoint was incident hypertension at weeks. Secondary endpoints were changes in systolic (SBP) and diastolic (DBP) blood pressure; adverse events...
Objectives: We evaluated antiviral effectiveness and safety of doravirine (DOR)-based regimens in people with HIV (PWH) routine clinical practice. Design: A retrospective, noninterventional study across 16 sites five European countries [United Kingdom (UK), France, Spain, Belgium, Netherlands]. Methods: The was conducted both treatment-experienced treatment-naive PWH who either switched to, or initiated DOR-containing antiretroviral therapy (ART). primary endpoints were virological success...
As recommended by the French ANRS programme for surveillance of HIV-1 resistance, we estimated prevalence transmitted drug resistance-associated mutations (RAMs) in antiretroviral-naive, chronically HIV-1-infected patients. RAMs were sought samples from 661 newly diagnosed patients 2010/11 at 36 HIV clinical care centres. Weighted analyses used to derive representative estimates percentage with RAMs. At patient inclusion, virus protease (PR) or reverse transcriptase (RT) was 9.0% (95% CI...
Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) >50 copies/mL. The protease and reverse transcriptase (RT) genes were systematically sequenced samples from 756 VL copies/mL 2009. genotyping results interpreted for each antiretroviral (ARV) by using the ANRS algorithm v21. Weighted analyses used to derive representative estimates percentages patients. Prevalence rates compared those obtained 2004 among >1000 Sequences 506 Sequencing was successful 45%,...
Abstract Background Our study describes the prevalence of transmitted drug resistance (TDR) among 1318 French patients diagnosed at time primary HIV-1 infection (PHI) in 2007–12. Methods resistance-associated mutations (RAMs) were characterized using both 2009 WHO list and ANRS algorithm. A genotypic susceptibility score was estimated for each first-line recommended ART combination. Results Patients mainly MSM (72.6%). Non-B variants identified 33.7% patients. The proportion TDR as 11.7%...
Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to dolutegravir (DTG)-based may improve lipid profile. European Network for AIDS Treatment 022 Study (NEAT022) is European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged ≥50 years or with Framingham score ≥10% were eligible if HIV RNA was <50 copies/mL. Patients switch PI/r DTG immediately (DTG-I) at week 48 (DTG-D). Week 96 endpoints proportion of...
Lenalidomide, an oral immunomodulating agent, has shown promising activity in HIV-infected individuals with Kaposi's sarcoma (KS). This single-arm, multicenter, open-label, Gehan's two-stage phase II trial evaluated the efficacy and safety of lenalidomide patients progressive KS despite previous chemotherapy (NCT01282047, ANRS 154 Lenakap trial). The primary endpoint was rate partial response (PR) or complete (CR) at week 24, by both study investigators using Physical Global Assessment...